CoChat

Reprogramming immunosuppressive myeloid cells facilitates immunotherapy for colorectal cancer

Open access

The DOI matches its Crossref record; 65 of the 66 references it cites were found in a registry or an index.

Abstract

Immune checkpoint blockade (ICB) has a limited effect on colorectal cancer, underlining the requirement of co‐targeting the complementary mechanisms. Here, we identified prostaglandin E2 (PGE 2 ) receptor 4 (EP4) as the master regulator of immunosuppressive myeloid cells (IMCs), which are the major driver of resistance to ICB therapy. PGE 2 ‐bound EP4 promotes the differentiation of immunosuppressive M2 macrophages and myeloid‐derived suppressor cells (MDSCs) and reduces the expansion of immunostimulated M1 macrophages. To explore the immunotherapeutic role of EP4 signaling, we developed a novel and selective EP4 antagonist TP‐16. TP‐16 effectively blocked the function of IMCs and enhanced cytotoxic T‐cell‐mediated tumor elimination in vivo . Cell co‐culture experiments revealed that TP‐16 promoted T‐cell proliferation, which was impaired by tumor‐derived CD11b + myeloid cells. Notably, TP‐16 and anti‐PD‐1 combination therapy significantly impeded tumor progression and prolonged mice survival. We further demonstrated that TP‐16 increased responsiveness to anti‐PD‐1 therapy in an IMC‐related spontaneous colorectal cancer mouse model. In summary, this study demonstrates that inhibition of EP4‐expressing IMCs may offer a potential strategy for enhancing the efficacy of immunotherapy for colorectal cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.202012798

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 EP4 is a master regulator of IMCs The expression of EP subtypes in bone marrow myeloid cells and colon tumor myeloid cells. The short black lines indicate individual expressions, and the blue and yellow lines indicate the average expression level in each condition. The gray dotted lines represent the overall average between Ptger1 and Ptger3 or Ptger2 and Ptger4.The expression of EP subtypes in CD11b+ cells isolated from tumor tissues and spleen of CT26 tumor‐bearing mice by magnetic bead separation (n = 3).Schematic diagram of the granulocyte–macrophage colony‐stimulating factor (GM‐CSF)/interleukin (IL)‐4‐induced mouse monocyte DCs/macrophages differentiation assay. Cells were treated with specific antagonists of distinct EP receptors: ONO‐8711, EP1; PF‐04418948, EP2; L‐798106, EP3; and E7046, EP4.Representative flow cytometry plots revealing the effects of prostaglandin E2 (PGE2) and EP1‐4 antagonists on mouse bone marrow monocyte dendritic cell (DC)/macrophage differentiation (n = 3).The frequencies of F4/80+CD11C− macrophages and F4/80−CD11C+ DCs under varying treatments as analyzed by flow cytometry analysis (n = 3).Schematic representation of the GM‐CSF/IL‐6‐induced mouse bone marrow monocyte myeloid‐derived suppressor cell (MDSC) differentiation assay (n = 3).Representative flow cytometry plots revealing the effects of PGE2 and EP1‐4 antagonists on mouse bone marrow‐derived‐MDSC differentiation. Upper subpanel: vehicle group and PGE2 group. Lower subpanel: ONO‐8711 (EP1 antagonist) group, PF‐04418948 (EP2 antagonist) group, L‐798106 (EP3 antagonist) group, and E7046 (EP4 antagonist) group. (n = 3).The frequencies of Ly6C+Ly6G− mMDSC and Ly6CmidLy6G+ PMN‐MDSCs under varied treatments as analyzed by flow cytometry analysis (n = 3). Data information: Data are presented as mean ± SEM. (A) Kolmogorov–Smirnov test; (E, H) two‐tailed unpaired Student’s t‐test was performed; *P < 0.05; **P < 0.01; ***P < 0.001. Exact P values and statistical tests are listed in Appendix Table S8.
Figure 1 EP4 is a master regulator of IMCs The expression of EP subtypes in bone marrow myeloid cells and colon tumor myeloid cells. The short black lines indicate individual expressions, and the blue and yellow lines indicate the average expression level in each condition. The gray dotted lines represent the overall average between Ptger1 and Ptger3 or Ptger2 and Ptger4.The expression of EP subtypes in CD11b+ cells isolated from tumor tissues and spleen of CT26 tumor‐bearing mice by magnetic bead separation (n = 3).Schematic diagram of the granulocyte–macrophage colony‐stimulating factor (GM‐CSF)/interleukin (IL)‐4‐induced mouse monocyte DCs/macrophages differentiation assay. Cells were treated with specific antagonists of distinct EP receptors: ONO‐8711, EP1; PF‐04418948, EP2; L‐798106, EP3; and E7046, EP4.Representative flow cytometry plots revealing the effects of prostaglandin E2 (PGE2) and EP1‐4 antagonists on mouse bone marrow monocyte dendritic cell (DC)/macrophage differentiation (n = 3).The frequencies of F4/80+CD11C− macrophages and F4/80−CD11C+ DCs under varying treatments as analyzed by flow cytometry analysis (n = 3).Schematic representation of the GM‐CSF/IL‐6‐induced mouse bone marrow monocyte myeloid‐derived suppressor cell (MDSC) differentiation assay (n = 3).Representative flow cytometry plots revealing the effects of PGE2 and EP1‐4 antagonists on mouse bone marrow‐derived‐MDSC differentiation. Upper subpanel: vehicle group and PGE2 group. Lower subpanel: ONO‐8711 (EP1 antagonist) group, PF‐04418948 (EP2 antagonist) group, L‐798106 (EP3 antagonist) group, and E7046 (EP4 antagonist) group. (n = 3).The frequencies of Ly6C+Ly6G− mMDSC and Ly6CmidLy6G+ PMN‐MDSCs under varied treatments as analyzed by flow cytometry analysis (n = 3). Data information: Data are presented as mean ± SEM. (A) Kolmogorov–Smirnov test; (E, H) two‐tailed unpaired Student’s t‐test was performed; *P < 0.05; **P < 0.01; ***P < 0.001. Exact P values and statistical tests are listed in Appendix Table S8.CC BY · PubMed Central
Figure 2 Discovery and characterization of a potent and selective EP4 antagonist, TP‐16 Chemical structure of TP‐16.Dose–effect curve of TP‐16 in GloSensor™ cAMP assay in EP4‐ expressing 293 cells (n = 3).Dose–effect curves of TP‐16 in PGE2‐induced calcium flux assay (n = 3).The Schild plot of PGE2 in the presence of varying concentrations of TP‐16. TP‐16 shifted the dose–response curve of PGE2‐induced intracellular cAMP levels in a dose‐dependent manner (n = 3).The pA2 value and slope of the Schild plot.Docked pose of TP‐16 with critical residues in the putative binding pocket of human EP4 protein. EP4 is shown as a color cartoon, the residues important for the interaction are depicted in magenta sticks, and TP‐16 is shown as a cyan stick figure.The LIGPLOT diagram summarizes key interactions between TP‐16 (purple lines) and residues that originate from EP4. T69, T76, T168, and R316 establish hydrogen bonds with TP‐16. Semicircles with radiating lines indicate non‐polar interactions. Data information: Data are presented as mean ± SEM from three independent experiments with similar results.
Figure 2 Discovery and characterization of a potent and selective EP4 antagonist, TP‐16 Chemical structure of TP‐16.Dose–effect curve of TP‐16 in GloSensor™ cAMP assay in EP4‐ expressing 293 cells (n = 3).Dose–effect curves of TP‐16 in PGE2‐induced calcium flux assay (n = 3).The Schild plot of PGE2 in the presence of varying concentrations of TP‐16. TP‐16 shifted the dose–response curve of PGE2‐induced intracellular cAMP levels in a dose‐dependent manner (n = 3).The pA2 value and slope of the Schild plot.Docked pose of TP‐16 with critical residues in the putative binding pocket of human EP4 protein. EP4 is shown as a color cartoon, the residues important for the interaction are depicted in magenta sticks, and TP‐16 is shown as a cyan stick figure.The LIGPLOT diagram summarizes key interactions between TP‐16 (purple lines) and residues that originate from EP4. T69, T76, T168, and R316 establish hydrogen bonds with TP‐16. Semicircles with radiating lines indicate non‐polar interactions. Data information: Data are presented as mean ± SEM from three independent experiments with similar results.CC BY · PubMed Central
Figure EV1 Antagonistic activity, pharmacokinetic profiles, and safety of TP‐16 ADose–response of TP‐16 in cAMP reporter gene assay in HEK293 cells. Data are presented as mean ± SEM derived from three independent experiments (n = 3).BDose–effect curves of TP‐16 in PGE2‐induced β‐arrestin Tango assay. Data are presented as mean ± SEM derived from three independent experiments (n = 3).C–EThe antagonistic activities of TP‐16 on EP4 were determined by a calcium flux assay by overexpressing Gα16 protein in CHO cells. Dose–response curves of TP‐16 against EP4: monkey (C), rat (D), and mouse (E). Data are presented as mean ± SEM derived from three independent experiments (n = 3).F, GThe plasma concentration over time profiles of TP‐16 after intravenous and oral administration of TP‐16 at a dose of 1 and 10 mg/kg, respectively. Results are presented as mean ± SEM of three CD1 mice (n = 3).HBody weights of male and female SD rats orally administered with TP‐16 (100 mg/kg/day) in 14‐day repeat‐dose. Data are presented as means ± SD (n = 3/sex/group). Data information: Data are presented as mean ± SEM except for H.
Figure EV1 Antagonistic activity, pharmacokinetic profiles, and safety of TP‐16 ADose–response of TP‐16 in cAMP reporter gene assay in HEK293 cells. Data are presented as mean ± SEM derived from three independent experiments (n = 3).BDose–effect curves of TP‐16 in PGE2‐induced β‐arrestin Tango assay. Data are presented as mean ± SEM derived from three independent experiments (n = 3).C–EThe antagonistic activities of TP‐16 on EP4 were determined by a calcium flux assay by overexpressing Gα16 protein in CHO cells. Dose–response curves of TP‐16 against EP4: monkey (C), rat (D), and mouse (E). Data are presented as mean ± SEM derived from three independent experiments (n = 3).F, GThe plasma concentration over time profiles of TP‐16 after intravenous and oral administration of TP‐16 at a dose of 1 and 10 mg/kg, respectively. Results are presented as mean ± SEM of three CD1 mice (n = 3).HBody weights of male and female SD rats orally administered with TP‐16 (100 mg/kg/day) in 14‐day repeat‐dose. Data are presented as means ± SD (n = 3/sex/group). Data information: Data are presented as mean ± SEM except for H.CC BY · PubMed Central
Figure 3 EP4 antagonist TP‐16 robustly suppresses the tumor growth in murine syngeneic tumor models Schematic illustration of the establishment of the murine syngeneic tumor models and drug treatment schedule. Established tumor models were orally treated daily with vehicle or TP‐16 when tumor volumes reached 100‐200 mm3.The anti‐tumor activities of E7046 (150 mg/kg) and TP‐16 (37.5, 75, and 150 mg/kg) in CT26 tumor‐bearing BALB/c mice (n = 11 per group). Tumor growth curves in the CT26 model (left panel). Bar graphs show the individual changes in tumor growth relative to after and before drug administration (right panel). Tumor volumes reached 100–200 mm3 on day 7.Representative graph showing that the anti‐tumor activity of TP‐16 is lost in CT26 tumors engrafted into BALB/c nude mice (left panel) (n = 8). Bar graphs show the individual changes in tumor growth relative to after and before drug administration (right panel). Tumor volumes reached 100–200 mm3 on day 7.Single‐cell suspensions of tumor tissues from CT26 tumor‐bearing BALB/c mice treated with vehicle or TP‐16 for 2 weeks were analyzed for immune cell infiltration by flow cytometry analysis. Representative flow cytometry and dot plots of intratumoral frequencies of CD8+ T cells (n = 5).Growth curves (left panel) and relative change after 18 days treatment (right panel) in colon cancer (MC38) xenograft tumors in C57BL/6 mice (n = 7). Tumor volumes reached 100–200 mm3 on day 7.Single‐cell suspensions of tumor tissues from MC38 tumor‐bearing C57BL/6 mice treated with vehicle or TP‐16 for 2 weeks were analyzed for immune cell infiltration by flow cytometry analysis. Representative flow cytometry and dot plots of intratumoral frequencies of CD8+ T cells (n = 5).The representative bioluminescence images (left panel) and quantitative growth curves (right panel) of an orthotopic colorectal cancer mouse model, CT26‐Luc model (n = 4). Data information: Data are presented as mean ± SEM. (B) One‐way analysis of variance (ANOVA), Tukey's multiple comparison test; *P < 0.05. (C‐G) two‐tailed unpaired Student’s t‐test was performed; *P < 0.05; **P < 0.01. Exact P values and statistical tests are listed in Appendix Table S8. Source data are available online for this figure.
Figure 3 EP4 antagonist TP‐16 robustly suppresses the tumor growth in murine syngeneic tumor models Schematic illustration of the establishment of the murine syngeneic tumor models and drug treatment schedule. Established tumor models were orally treated daily with vehicle or TP‐16 when tumor volumes reached 100‐200 mm3.The anti‐tumor activities of E7046 (150 mg/kg) and TP‐16 (37.5, 75, and 150 mg/kg) in CT26 tumor‐bearing BALB/c mice (n = 11 per group). Tumor growth curves in the CT26 model (left panel). Bar graphs show the individual changes in tumor growth relative to after and before drug administration (right panel). Tumor volumes reached 100–200 mm3 on day 7.Representative graph showing that the anti‐tumor activity of TP‐16 is lost in CT26 tumors engrafted into BALB/c nude mice (left panel) (n = 8). Bar graphs show the individual changes in tumor growth relative to after and before drug administration (right panel). Tumor volumes reached 100–200 mm3 on day 7.Single‐cell suspensions of tumor tissues from CT26 tumor‐bearing BALB/c mice treated with vehicle or TP‐16 for 2 weeks were analyzed for immune cell infiltration by flow cytometry analysis. Representative flow cytometry and dot plots of intratumoral frequencies of CD8+ T cells (n = 5).Growth curves (left panel) and relative change after 18 days treatment (right panel) in colon cancer (MC38) xenograft tumors in C57BL/6 mice (n = 7). Tumor volumes reached 100–200 mm3 on day 7.Single‐cell suspensions of tumor tissues from MC38 tumor‐bearing C57BL/6 mice treated with vehicle or TP‐16 for 2 weeks were analyzed for immune cell infiltration by flow cytometry analysis. Representative flow cytometry and dot plots of intratumoral frequencies of CD8+ T cells (n = 5).The representative bioluminescence images (left panel) and quantitative growth curves (right panel) of an orthotopic colorectal cancer mouse model, CT26‐Luc model (n = 4). Data information: Data are presented as mean ± SEM. (B) One‐way analysis of variance (ANOVA), Tukey's multiple comparison test; *P < 0.05. (C‐G) two‐tailed unpaired Student’s t‐test was performed; *P < 0.05; **P < 0.01. Exact P values and statistical tests are listed in Appendix Table S8. Source data are available online for this figure.CC BY · PubMed Central
Figure EV2 Effect of EP4 inhibition by TP‐16 on tumor growth and subsets of intratumoral immune cells AThe growth curves of CT26 xenograft tumors in BALB/c mice. CT26 tumor‐bearing mice were treated with TP‐16 (75 mg/kg, p.o., daily) or celecoxib (100 mg/kg, p.o., daily) for 16 days when tumor volumes reached 100‐200 mm3 (day 7). Data are presented as mean ± SEM. One‐way analysis of variance (ANOVA), Tukey's multiple comparison; ***P < 0.001. n = 6.B, CThe anti‐tumor activity of TP‐16 on 4T1 xenograft tumors in BALB/c mice and Pan02 xenograft tumors in C57BL/6 mice. Mice were treated with TP‐16 (75 mg/kg, po, daily) when tumor volumes reached 100–200 mm3 (day 7). Data are presented as mean ± SEM. A two‐tailed unpaired Student’s t‐test was performed; **P < 0.01; ***P < 0.001 (n = 8).D, ESingle‐cell suspensions of tumors from CT26‐bearing BALB/c mice treated with vehicle or 75 mg/kg TP‐16 for 2 weeks were analyzed for intratumoral immune cells by flow cytometry analysis. Representative graphs and quantification of CD11b+F4/80+ macrophages (D) and CD45+CD11b+CD11c+MHC II+ dendritic cells (DCs) (E). Data are presented as mean ± SEM. A two‐tailed unpaired Student’s t‐test was performed; *P < 0.05; **P < 0.01 (n = 5).FRepresentative graphs and quantification of TNF‐α in CD11b+ cells isolated from the CT26 xenograft tumors (n = 6). Data are presented as mean ± SEM. A two‐tailed unpaired Student’s t‐test was performed, ***P < 0.001 versus the vehicle control group.GRepresentative immunofluorescence images of p‐CREB in CD11b+ cells of CT26 tumor tissue. Scale bars, 50 μm.HThe changes of myeloid cell compartment in an orthotopic colorectal cancer mouse model, CT26‐Luc model (n = 4). A two‐tailed unpaired Student’s t‐test was performed, *P < 0.05, **P < 0.01 versus vehicle control group.I, JRepresentative graphs and quantification of CD4 + T‐cell activation markers IFN‐γ (H) and TNF‐α (I) (n = 5). Data are presented as mean ± SEM derived from three independent experiments. A two‐tailed unpaired Student’s t‐test was performed, ***P < 0.001 versus the vehicle control group. Source data are available online for this figure.
Figure EV2 Effect of EP4 inhibition by TP‐16 on tumor growth and subsets of intratumoral immune cells AThe growth curves of CT26 xenograft tumors in BALB/c mice. CT26 tumor‐bearing mice were treated with TP‐16 (75 mg/kg, p.o., daily) or celecoxib (100 mg/kg, p.o., daily) for 16 days when tumor volumes reached 100‐200 mm3 (day 7). Data are presented as mean ± SEM. One‐way analysis of variance (ANOVA), Tukey's multiple comparison; ***P < 0.001. n = 6.B, CThe anti‐tumor activity of TP‐16 on 4T1 xenograft tumors in BALB/c mice and Pan02 xenograft tumors in C57BL/6 mice. Mice were treated with TP‐16 (75 mg/kg, po, daily) when tumor volumes reached 100–200 mm3 (day 7). Data are presented as mean ± SEM. A two‐tailed unpaired Student’s t‐test was performed; **P < 0.01; ***P < 0.001 (n = 8).D, ESingle‐cell suspensions of tumors from CT26‐bearing BALB/c mice treated with vehicle or 75 mg/kg TP‐16 for 2 weeks were analyzed for intratumoral immune cells by flow cytometry analysis. Representative graphs and quantification of CD11b+F4/80+ macrophages (D) and CD45+CD11b+CD11c+MHC II+ dendritic cells (DCs) (E). Data are presented as mean ± SEM. A two‐tailed unpaired Student’s t‐test was performed; *P < 0.05; **P < 0.01 (n = 5).FRepresentative graphs and quantification of TNF‐α in CD11b+ cells isolated from the CT26 xenograft tumors (n = 6). Data are presented as mean ± SEM. A two‐tailed unpaired Student’s t‐test was performed, ***P < 0.001 versus the vehicle control group.GRepresentative immunofluorescence images of p‐CREB in CD11b+ cells of CT26 tumor tissue. Scale bars, 50 μm.HThe changes of myeloid cell compartment in an orthotopic colorectal cancer mouse model, CT26‐Luc model (n = 4). A two‐tailed unpaired Student’s t‐test was performed, *P < 0.05, **P < 0.01 versus vehicle control group.I, JRepresentative graphs and quantification of CD4 + T‐cell activation markers IFN‐γ (H) and TNF‐α (I) (n = 5). Data are presented as mean ± SEM derived from three independent experiments. A two‐tailed unpaired Student’s t‐test was performed, ***P < 0.001 versus the vehicle control group. Source data are available online for this figure.CC BY · PubMed Central
Figure 4 EP4 antagonist TP‐16 reprograms tumor‐associated myeloid cells (IMCs) and enhances anti‐tumor immunity A, BTumors from CT26 tumor‐bearing BALB/c mice treated with vehicle or TP‐16 for 2 weeks were harvested, and tumor single‐cell suspensions were analyzed for tumor‐associated myeloid cells by flow cytometry analysis. Representative graphs and quantification of F4/80+MHC‐II+ immunosuppressive myeloid cells (IMCs)‐M1 macrophages (A) and F4/80+CD206+ IMCs‐M2 macrophages (B) gated on CD45+CD11b+ myeloid cells (n = 5).CRepresentative flow cytometry analysis and quantification of Ly6C+Ly6G‐ IMC‐monocytic myeloid‐derived suppressor cell (mMDSC) and Ly6CmidLy6G+ IMC‐PMN‐MDSC frequencies gated on CD45+CD11b+ myeloid cells (n = 5).D–GRelative expression of selected M1, M2, and MDSC markers on flow‐sorted M1 macrophages (D), M2 macrophages (E), mMDSCs (F), and PMN‐MDSCs (G) from CT26 tumors. Data are normalized to β‐actin expression levels (n = 5).H–KRepresentative flow analysis and quantification of CD8+ T‐cell activation markers: Granzyme B (H), IFN‐γ (I), TNF‐α (J), and PD‐1 (K) (n = 5). Data information: Data are presented as mean ± SEM. (A‐K) Two‐tailed unpaired Student’s t‐test; *P < 0.05; **P < 0.01; ***P < 0.001. Exact P values and statistical tests are listed in Appendix Table S8.
Figure 4 EP4 antagonist TP‐16 reprograms tumor‐associated myeloid cells (IMCs) and enhances anti‐tumor immunity A, BTumors from CT26 tumor‐bearing BALB/c mice treated with vehicle or TP‐16 for 2 weeks were harvested, and tumor single‐cell suspensions were analyzed for tumor‐associated myeloid cells by flow cytometry analysis. Representative graphs and quantification of F4/80+MHC‐II+ immunosuppressive myeloid cells (IMCs)‐M1 macrophages (A) and F4/80+CD206+ IMCs‐M2 macrophages (B) gated on CD45+CD11b+ myeloid cells (n = 5).CRepresentative flow cytometry analysis and quantification of Ly6C+Ly6G‐ IMC‐monocytic myeloid‐derived suppressor cell (mMDSC) and Ly6CmidLy6G+ IMC‐PMN‐MDSC frequencies gated on CD45+CD11b+ myeloid cells (n = 5).D–GRelative expression of selected M1, M2, and MDSC markers on flow‐sorted M1 macrophages (D), M2 macrophages (E), mMDSCs (F), and PMN‐MDSCs (G) from CT26 tumors. Data are normalized to β‐actin expression levels (n = 5).H–KRepresentative flow analysis and quantification of CD8+ T‐cell activation markers: Granzyme B (H), IFN‐γ (I), TNF‐α (J), and PD‐1 (K) (n = 5). Data information: Data are presented as mean ± SEM. (A‐K) Two‐tailed unpaired Student’s t‐test; *P < 0.05; **P < 0.01; ***P < 0.001. Exact P values and statistical tests are listed in Appendix Table S8.CC BY · PubMed Central
Figure EV3 TP‐16 suppresses M2 macrophage differentiation and reverses T‐cell proliferation when cultured with tumor‐infiltrating CD11b+ myeloid cells AMouse bone marrow cells were cultured with M‐CSF/IL‐4/PGE2 for 6 days and varied concentrations of TP‐16 was simultaneously (day 0) or sequentially (day 3) added. The generation of M2 macrophages (F4/80+CD206+) was analyzed by flow cytometry analysis. Si: simultaneous TP‐16 treatment; Se: sequential TP‐16 treatment. Data are presented as mean ± SEM. One‐way analysis of variance (ANOVA) and Tukey's multiple comparison test were performed; ***P < 0.001 (n = 3).B, CMouse bone marrow‐derived macrophages (BMMs) were stimulated with 20 ng/ml mouse recombinant IL‐4 alone or in combination with 100 nM PGE2, in the absence or presence of 10 μM TP‐16 for the indicated time. The expression of p‐STAT3705, p‐STAT3727, p‐STAT3, p‐AKT473, p‐AKT308, and AKT was detected by Western blotting. GAPDH served as the loading control.D, ERepresentative histograms (D) and percentage (E) of CD4+ T‐cell proliferation at a ratio of 2:1, 1:1, and 1:2 CD4+ T cells to CD11b+ myeloid cells collected from CT26 tumor‐bearing mice at 2 weeks post‐treatment with vehicle or 75 mg/kg TP‐16. All data are presented as mean ± SEM derived from three independent experiments (n = 3). A two‐tailed unpaired Student’s t‐test was performed, ***P < 0.001. Source data are available online for this figure.
Figure EV3 TP‐16 suppresses M2 macrophage differentiation and reverses T‐cell proliferation when cultured with tumor‐infiltrating CD11b+ myeloid cells AMouse bone marrow cells were cultured with M‐CSF/IL‐4/PGE2 for 6 days and varied concentrations of TP‐16 was simultaneously (day 0) or sequentially (day 3) added. The generation of M2 macrophages (F4/80+CD206+) was analyzed by flow cytometry analysis. Si: simultaneous TP‐16 treatment; Se: sequential TP‐16 treatment. Data are presented as mean ± SEM. One‐way analysis of variance (ANOVA) and Tukey's multiple comparison test were performed; ***P < 0.001 (n = 3).B, CMouse bone marrow‐derived macrophages (BMMs) were stimulated with 20 ng/ml mouse recombinant IL‐4 alone or in combination with 100 nM PGE2, in the absence or presence of 10 μM TP‐16 for the indicated time. The expression of p‐STAT3705, p‐STAT3727, p‐STAT3, p‐AKT473, p‐AKT308, and AKT was detected by Western blotting. GAPDH served as the loading control.D, ERepresentative histograms (D) and percentage (E) of CD4+ T‐cell proliferation at a ratio of 2:1, 1:1, and 1:2 CD4+ T cells to CD11b+ myeloid cells collected from CT26 tumor‐bearing mice at 2 weeks post‐treatment with vehicle or 75 mg/kg TP‐16. All data are presented as mean ± SEM derived from three independent experiments (n = 3). A two‐tailed unpaired Student’s t‐test was performed, ***P < 0.001. Source data are available online for this figure.CC BY · PubMed Central
Figure 5 EP4 antagonist TP‐16 reverses the immunosuppressive effects of PGE2 on myeloid differentiation and activation A, BM‐CSF‐induced mouse bone marrow‐derived macrophages (BMMs) were stimulated with 50 ng/ml mouse recombinant IFN‐γ (A) or 20 ng/ml mouse recombinant IL‐4 (B) in the absence or presence of PGE2 ± varying concentrations of TP‐16 for 12 h. The mRNA levels of selected M1 markers (Cxcl10 and Tnfa) and M2 markers (Arg‐1 and Ym‐1) were measured by qPCR. Data are normalized to β‐actin expression levels (n = 3).CBone marrow cells were cultured with 40 ng/ml GM‐CSF/IL‐6 or co‐stimulated with PGE2 ± varying concentrations of TP‐16 for 6 days. Representative quantification of Ly6C+Ly6G− monocytic myeloid‐derived suppressor cells (mMDSCs) and Ly6CmidLy6G+ PMN‐MDSCs (n = 3).DBone marrow cells were treated with GM‐CSF/IL‐6 for 6 days to induce MDSCs and thereafter with PGE2 ± varying concentrations of TP‐16 for 12 h. The mRNA levels of selected MDSC markers (Arg‐1, Ptgs2, Il‐4, and Il‐10) were measured by qPCR. Data are normalized to β‐actin expression levels (n = 3).E, FIn vitro T‐cell suppression activity of CT26‐ tumor‐infiltrating CD11b+ myeloid cells collected at 2 weeks post‐treatment with vehicle or 75 mg/kg TP‐16. CD8+ T cells were labeled with CFSE and then stimulated with CD3/CD28 antibodies for 3 days in the absence or presence of tumor‐infiltrating CD11b+ myeloid cells from vehicle‐ or 75 mg/kg TP‐16‐treated CT26 tumors. Representative flow cytometry histograms (E) and percentages (F) of proliferating CD8+ T cells when plated in a ratio of 2:1, 1:1, and 1:2 CD8+ T cells to CD11b+ myeloid cells (n = 3). Data information: Data are presented as mean ± SEM. (A‐D, F) One‐way analysis of variance (s), Tukey's multiple comparison; *P < 0.05; **P < 0.01; ***P < 0.001. Exact P values and statistical tests are listed in Appendix Table S8.
Figure 5 EP4 antagonist TP‐16 reverses the immunosuppressive effects of PGE2 on myeloid differentiation and activation A, BM‐CSF‐induced mouse bone marrow‐derived macrophages (BMMs) were stimulated with 50 ng/ml mouse recombinant IFN‐γ (A) or 20 ng/ml mouse recombinant IL‐4 (B) in the absence or presence of PGE2 ± varying concentrations of TP‐16 for 12 h. The mRNA levels of selected M1 markers (Cxcl10 and Tnfa) and M2 markers (Arg‐1 and Ym‐1) were measured by qPCR. Data are normalized to β‐actin expression levels (n = 3).CBone marrow cells were cultured with 40 ng/ml GM‐CSF/IL‐6 or co‐stimulated with PGE2 ± varying concentrations of TP‐16 for 6 days. Representative quantification of Ly6C+Ly6G− monocytic myeloid‐derived suppressor cells (mMDSCs) and Ly6CmidLy6G+ PMN‐MDSCs (n = 3).DBone marrow cells were treated with GM‐CSF/IL‐6 for 6 days to induce MDSCs and thereafter with PGE2 ± varying concentrations of TP‐16 for 12 h. The mRNA levels of selected MDSC markers (Arg‐1, Ptgs2, Il‐4, and Il‐10) were measured by qPCR. Data are normalized to β‐actin expression levels (n = 3).E, FIn vitro T‐cell suppression activity of CT26‐ tumor‐infiltrating CD11b+ myeloid cells collected at 2 weeks post‐treatment with vehicle or 75 mg/kg TP‐16. CD8+ T cells were labeled with CFSE and then stimulated with CD3/CD28 antibodies for 3 days in the absence or presence of tumor‐infiltrating CD11b+ myeloid cells from vehicle‐ or 75 mg/kg TP‐16‐treated CT26 tumors. Representative flow cytometry histograms (E) and percentages (F) of proliferating CD8+ T cells when plated in a ratio of 2:1, 1:1, and 1:2 CD8+ T cells to CD11b+ myeloid cells (n = 3). Data information: Data are presented as mean ± SEM. (A‐D, F) One‐way analysis of variance (s), Tukey's multiple comparison; *P < 0.05; **P < 0.01; ***P < 0.001. Exact P values and statistical tests are listed in Appendix Table S8.CC BY · PubMed Central
Figure 6 EP4 antagonist TP‐16 improves the efficacy of immune checkpoint blockade and induces a durable anti‐tumor immune response in CT26 tumor‐bearing mice The growth of CT26 tumor volume when treated with vehicle, TP‐16 (75 mg/kg, p.o., daily), anti‐PD‐1 antibody (50 μg, i.p., twice weekly) or their combination (left) and percent change in tumor volumes between days 0 and 20 (right) (n = 12).BALB/c mice with subcutaneous CT26 tumors were treated with vehicle, TP‐16 (75 mg/kg, p.o., daily), PD‐1 antibody (50 μg, i.p., twice weekly) or combined therapies for 2 weeks. Animal survival (time to tumor burden reaching 2,000 mm3) was analyzed by the Kaplan–Meier method using GraphPad Prism (n = 10). P values were calculated using the log‐rank test.Representative immunofluorescence staining images of tumor sections from CT26 tumor‐bearing mice stained for CD8 and DAPI. Scale bars, 50 μm.Representative immunostaining images of tumor sections from CT26 tumor‐bearing mice stained for p‐STAT3, p‐AKT, and PD‐L1. Scale bars, 100 μm.Transcriptome profile changes mediated by the synergy of TP‐16 and anti‐PD‐1 analyzed using Agilent SurePrint G3 Mouse GE V2.0 Microarray. Venn diagrams depicting the number of changed genes (FC ≥ 2 or FC ≤ −2, P ≤ 0.05) compared with vehicle control following TP‐16, anti‐PD‐1 antibody, or TP‐16 and anti‐PD‐1 combined therapy.The heatmap of T‐cell activation biomarkers for RNA‐seq analysis. The unit of heatmap scale is expression value after centering and scaling by genes. Data information: Data are presented as mean ± SEM. (A) One‐way analysis of variance one‐way analysis (ANOVA), Tukey's multiple comparison; **P < 0.01; ***P < 0.001. (B) log‐rank test; *P < 0.05; **P < 0.01; ***P < 0.001. Exact P values and statistical tests are listed in Appendix Table S8. Source data are available online for this figure.
Figure 6 EP4 antagonist TP‐16 improves the efficacy of immune checkpoint blockade and induces a durable anti‐tumor immune response in CT26 tumor‐bearing mice The growth of CT26 tumor volume when treated with vehicle, TP‐16 (75 mg/kg, p.o., daily), anti‐PD‐1 antibody (50 μg, i.p., twice weekly) or their combination (left) and percent change in tumor volumes between days 0 and 20 (right) (n = 12).BALB/c mice with subcutaneous CT26 tumors were treated with vehicle, TP‐16 (75 mg/kg, p.o., daily), PD‐1 antibody (50 μg, i.p., twice weekly) or combined therapies for 2 weeks. Animal survival (time to tumor burden reaching 2,000 mm3) was analyzed by the Kaplan–Meier method using GraphPad Prism (n = 10). P values were calculated using the log‐rank test.Representative immunofluorescence staining images of tumor sections from CT26 tumor‐bearing mice stained for CD8 and DAPI. Scale bars, 50 μm.Representative immunostaining images of tumor sections from CT26 tumor‐bearing mice stained for p‐STAT3, p‐AKT, and PD‐L1. Scale bars, 100 μm.Transcriptome profile changes mediated by the synergy of TP‐16 and anti‐PD‐1 analyzed using Agilent SurePrint G3 Mouse GE V2.0 Microarray. Venn diagrams depicting the number of changed genes (FC ≥ 2 or FC ≤ −2, P ≤ 0.05) compared with vehicle control following TP‐16, anti‐PD‐1 antibody, or TP‐16 and anti‐PD‐1 combined therapy.The heatmap of T‐cell activation biomarkers for RNA‐seq analysis. The unit of heatmap scale is expression value after centering and scaling by genes. Data information: Data are presented as mean ± SEM. (A) One‐way analysis of variance one‐way analysis (ANOVA), Tukey's multiple comparison; **P < 0.01; ***P < 0.001. (B) log‐rank test; *P < 0.05; **P < 0.01; ***P < 0.001. Exact P values and statistical tests are listed in Appendix Table S8. Source data are available online for this figure.CC BY · PubMed Central
Figure EV4 In vivo efficacy of EP4 antagonist (TP‐16) combined with immune checkpoint blockade Body weight of mice (CT26 syngeneic tumor model).The growth of MC38 tumors treated with vehicle, TP‐16 (75 mg/kg, po, daily), anti‐PD‐1 (50 μg, ip, twice weekly), and TP‐16 combined with anti‐PD‐1 antibody (n = 8 per group). Data are presented as mean ± SEM. One‐way ANOVA and Tukey's multiple comparison test were performed; *P < 0.05; **P < 0.01; ***P < 0.001.Body weight of mice (MC38 syngeneic tumor model).Representative immunofluorescence staining images of tumor sections from CT26 tumor‐bearing mice stained for myeloid‐derived suppressor cells (MDSCs; CD11b+Gr1+, upper panel) and M2 macrophages (CD11b+CD206+, lower panel). Scale bars, 50 μm.Cytokines (IL‐6 and CXCL1) in the peripheral blood of CT26 tumor‐bearing mice treated as indicated were measured by enzyme‐linked immunosorbent assay (ELISA) on the last day of treatment (n = 6). One‐way analysis of variance (ANOVA) and Turkey post hoc test were performed, *P < 0.05, **P < 0.01; ***P < 0.001.Pathway enrichment was analyzed based on the subsets of differentially expressed genes influenced by the combination therapy of TP‐16 and anti‐PD‐1 antibody. Source data are available online for this figure.
Figure EV4 In vivo efficacy of EP4 antagonist (TP‐16) combined with immune checkpoint blockade Body weight of mice (CT26 syngeneic tumor model).The growth of MC38 tumors treated with vehicle, TP‐16 (75 mg/kg, po, daily), anti‐PD‐1 (50 μg, ip, twice weekly), and TP‐16 combined with anti‐PD‐1 antibody (n = 8 per group). Data are presented as mean ± SEM. One‐way ANOVA and Tukey's multiple comparison test were performed; *P < 0.05; **P < 0.01; ***P < 0.001.Body weight of mice (MC38 syngeneic tumor model).Representative immunofluorescence staining images of tumor sections from CT26 tumor‐bearing mice stained for myeloid‐derived suppressor cells (MDSCs; CD11b+Gr1+, upper panel) and M2 macrophages (CD11b+CD206+, lower panel). Scale bars, 50 μm.Cytokines (IL‐6 and CXCL1) in the peripheral blood of CT26 tumor‐bearing mice treated as indicated were measured by enzyme‐linked immunosorbent assay (ELISA) on the last day of treatment (n = 6). One‐way analysis of variance (ANOVA) and Turkey post hoc test were performed, *P < 0.05, **P < 0.01; ***P < 0.001.Pathway enrichment was analyzed based on the subsets of differentially expressed genes influenced by the combination therapy of TP‐16 and anti‐PD‐1 antibody. Source data are available online for this figure.CC BY · PubMed Central
Figure 7 TP‐16 render anti‐PD‐1 antibody effective in AOM/DSS‐induced colorectal cancer model ASchematic diagram of the establishment of azoxymethane/dextran sodium sulfate (AOM/DSS)‐induced colorectal cancer model and drug therapy regimen. AOM/DSS‐induced colorectal tumor mice were treated with vehicle, TP‐16 (75 mg/kg, po, daily), PD‐1 antibody (50 μg, ip, twice weekly), or TP‐16 and anti‐PD‐1 combined. The endpoint was day 37 from treatment initiation.B–DRepresentative resected colons (B), total number of colon tumors per mouse (C, left) and tumor size distribution (C, right), and colon length (D) after 5 weeks of indicated treatment (n = 7).ERepresentative hematoxylin and eosin (H&E) staining and immunostaining for CD8, p‐STAT3, p‐AKT, and ARG‐1 of tumors treated with vehicle, TP‐16, anti‐PD‐1 antibody, or TP‐16 and anti‐PD‐1 combined. Scale bars, 500 μm (left images), 50 μm (right images).FQuantitative polymerase chain reaction (qPCR) analysis of the mRNA level of genes associated with immunosuppression (n = 6). Data information: Data are presented as mean ± SEM. (C, left panel) One‐way analysis of variance (ANOVA), Tukey's multiple comparison; **P < 0.01; ***P < 0.001. (C, right panel) two‐tailed unpaired Student’s t‐test; *P < 0.05; **P < 0.01; ***P < 0.001. (F) Exact P values and statistical tests are listed in Appendix Table S8. Source data are available online for this figure.
Figure 7 TP‐16 render anti‐PD‐1 antibody effective in AOM/DSS‐induced colorectal cancer model ASchematic diagram of the establishment of azoxymethane/dextran sodium sulfate (AOM/DSS)‐induced colorectal cancer model and drug therapy regimen. AOM/DSS‐induced colorectal tumor mice were treated with vehicle, TP‐16 (75 mg/kg, po, daily), PD‐1 antibody (50 μg, ip, twice weekly), or TP‐16 and anti‐PD‐1 combined. The endpoint was day 37 from treatment initiation.B–DRepresentative resected colons (B), total number of colon tumors per mouse (C, left) and tumor size distribution (C, right), and colon length (D) after 5 weeks of indicated treatment (n = 7).ERepresentative hematoxylin and eosin (H&E) staining and immunostaining for CD8, p‐STAT3, p‐AKT, and ARG‐1 of tumors treated with vehicle, TP‐16, anti‐PD‐1 antibody, or TP‐16 and anti‐PD‐1 combined. Scale bars, 500 μm (left images), 50 μm (right images).FQuantitative polymerase chain reaction (qPCR) analysis of the mRNA level of genes associated with immunosuppression (n = 6). Data information: Data are presented as mean ± SEM. (C, left panel) One‐way analysis of variance (ANOVA), Tukey's multiple comparison; **P < 0.01; ***P < 0.001. (C, right panel) two‐tailed unpaired Student’s t‐test; *P < 0.05; **P < 0.01; ***P < 0.001. (F) Exact P values and statistical tests are listed in Appendix Table S8. Source data are available online for this figure.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 65 references

Cited by

See all 115

Metadata

Authors
Lu, W., Yu, W., He, J., Liu, W., Yang, J., Lin, X., Zhang, Y., Wang, X., Jiang, W., Luo, J., Zhang, Q., Yang, H., Peng, S., Yi, Z., Ren, S., Chen, J., Siwko, S., Nussinov, R., Cheng, F., Zhang, H., & Liu, M.
Affiliations
  • East China Normal University (CN)
  • Second Military Medical University (CN)
  • Ningxia Medical University (CN)
  • Texas A&M University (US)
  • Tel Aviv University (IL)
  • Cleveland Clinic (US)
Corresponding author
  • Zhang, Hankun
  • Liu, Mingyao
Venue
EMBO Molecular Medicine
Published
2020-12-07
Volume
13
Issue
1
Pages
e12798-e12798
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W3112267375
Cited by
112
References
66
Citations by year
2026: 9 · 2025: 15 · 2024: 27 · 2023: 25 · 2022: 21 · 2021: 14 · 2020: 1
FWCI
5.43
Type
journal article
Language
en
Open access
Licence
Locations
  • EMBO Molecular Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (81972828, 81830083, 21977032, 2020ZX09201‐003)
  • Shanghai Municipal Education Commission (2017‐01‐07‐00‐05‐E00011)
  • Shenzhen (KQTD2017081060226082)
  • Shanghai Committee of Science and Technology (18431900500, 19ZR1473500, 18431900100)
  • National Key R&D Program of China (2018YFA0507000)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
colorectal cancer, EP4 receptor, prostaglandin E2, immunosuppressive myeloid cells, M2 macrophages, myeloid-derived suppressor cells, EP4 antagonist, immune checkpoint inhibitor resistance, anti-PD-1 combination therapy, T cell proliferation, tumor immunosuppression
MeSH terms
Myeloid-Derived Suppressor Cells, Animals, Immunotherapy, Colorectal Neoplasms, Myeloid Cells, Mice, Receptors, Prostaglandin E, EP4 Subtype

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reprogramming immunosuppressive myeloid cells facilitates immunotherapy for colorectal cancer. https://app.cochat.ai/papers/10.15252/emmm.202012798
The paper
Lu, W., Yu, W., He, J., Liu, W., Yang, J., Lin, X., Zhang, Y., Wang, X., Jiang, W., Luo, J., Zhang, Q., Yang, H., Peng, S., Yi, Z., Ren, S., Chen, J., Siwko, S., Nussinov, R., Cheng, F., . . . Liu, M. (2021). Reprogramming immunosuppressive myeloid cells facilitates immunotherapy for colorectal cancer. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202012798

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.